Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
Public ClinicalTrials.gov record NCT03297398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
Study identification
- NCT ID
- NCT03297398
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 114 participants
Conditions and interventions
Conditions
Interventions
- Group-1 (15mg, OPK-88004) Drug
- Group-2 (25 mg,OPK-88004) Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 45 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2018
- Primary completion
- Apr 17, 2019
- Completion
- Jun 9, 2019
- Last update posted
- Sep 15, 2021
2018 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group | Anniston | Alabama | 36207 | — |
| Clinical Trials Research | Lincoln | California | 95648 | — |
| Northern California Research | Sacramento | California | 95821 | — |
| Bayview Research Group, LLC - Valley Village | Valley Village | California | 91607 | — |
| South Florida Medical Research | Aventura | Florida | 33180 | — |
| APF Research, LLC | Miami | Florida | 33134 | — |
| Meridien Research - Brooksville | Spring Hill | Florida | 34609 | — |
| Florida Urology Partners | Tampa | Florida | 33615 | — |
| Advanced Clinical Research - Boise | Meridian | Idaho | 83642 | — |
| Regional Urology | Shreveport | Louisiana | 71106 | — |
| Centennial Medical Group | Elkridge | Maryland | 21075 | — |
| AccuMed Research Associates | Garden City | New York | 11530 | — |
| Manhattan Medical Research Practice PLLC | New York | New York | 10016 | — |
| Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville | Knoxville | Tennessee | 37920 | — |
| Clinical Trials of Texas, Inc. | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03297398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2021 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03297398 live on ClinicalTrials.gov.